<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144808">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137785</url>
  </required_header>
  <id_info>
    <org_study_id>CP0108</org_study_id>
    <nct_id>NCT02137785</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities</brief_title>
  <official_title>A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DUSA Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Levulan PDT is safe and effective in the
      treatment of actinic keratoses on the upper arms and hands
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete Clearance Rate</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AK Clearance Rate</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>{1 - [(number of AK lesions at follow-up)/(number of AK lesions at Baseline)]} x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AK Clearance Rate</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>{1 - [(number of AK lesions at follow-up)/(number of AK lesions at Baseline)]} x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Clearance Rate</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction Score</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject satisfaction score
= Excellent (very satisfied)
= Good (moderately satisfied)
= Fair (slightly satisfied)
= Poor (not satisfied at all)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>5 minutes after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>5 minutes after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>2 weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>During PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>5 minutes after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminolevulinic Acid (ALA)</intervention_name>
    <description>20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light</description>
    <arm_group_label>ALA</arm_group_label>
    <other_name>Levulan Kerastick</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Solution Vehicle</intervention_name>
    <description>Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BLU-U Blue Light Photodynamic Therapy Illuminator</intervention_name>
    <description>10 J/cm2 blue light delivered at 10mW/cm2</description>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Four to fifteen Grade 1/2 AKs on one upper extremity

        Exclusion Criteria:

          -  Pregnancy

          -  grade 3 and/or atypical &gt;1cm AKs within Treatment Area

          -  history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or
             photodermatosis

          -  lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated
             skin cancers within the Treatment Area

          -  skin pathology or condition which could interfere with the evaluation of the test
             product or requires the use of interfering topical or systemic therapy

          -  Subject is immunosuppressed

          -  unsuccessful outcome from previous ALA-PDT therapy

          -  currently enrolled in an investigational drug or device study

          -  has received an investigational drug or been treated with an investigational device
             within 30 days prior to the initiation of treatment

          -  known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl
             alcohol, laureth 4, polyethylene glycol)

          -  use of the following topical preparations on the extremity to be treated:

               -  Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.glycolic
                  acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%)
                  within 2 days of initiation of treatment.

               -  Cryotherapy within 2 weeks of initiation of treatment

               -  Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks of
                  initiation of treatment.

               -  Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU,
                  diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK
                  within 8 weeks of initiation of treatment.

          -  use of systemic retinoid therapy within 6 months of initiation of treatment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Marcus, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>DUSA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jim Berg</last_name>
    <phone>858-571-1800 Ext. 131</phone>
    <email>jberg@therapeuticsinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Piacquadio, MD</last_name>
    <phone>858-571-1800 Ext. 107</phone>
    <email>danp@therapeuticsinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galyna Cavallaro</last_name>
      <phone>510-797-0140</phone>
      <email>GalynaC@centerforderm.com</email>
    </contact>
    <investigator>
      <last_name>Sunil Dhawan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza Shafiq</last_name>
      <phone>858-657-1697</phone>
      <email>fshafiq@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Cosmetic Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Frisina</last_name>
      <phone>305-933-6716</phone>
    </contact>
    <investigator>
      <last_name>Brian Berman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MOORE Clinical Research, Inc</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carols Werner</last_name>
      <phone>813-948-7550</phone>
    </contact>
    <investigator>
      <last_name>Susan Barker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spencer Clinical Services</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juliana Accoily</last_name>
      <phone>727-572-1333</phone>
      <email>spencerclinicalservices@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>James Spencer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Cholewa</last_name>
      <phone>847-392-5440</phone>
    </contact>
    <investigator>
      <last_name>Michael Bukhalo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hoffman</last_name>
      <email>mhoffman@shideler.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Shideler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimmie Eads</last_name>
      <phone>317-837-6082</phone>
      <email>keads@indianatrials.com</email>
    </contact>
    <investigator>
      <last_name>Scott Guenthner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Roberts</last_name>
      <phone>763-571-4200</phone>
      <email>droberts@associatedskincare.com</email>
    </contact>
    <investigator>
      <last_name>Steven Kempers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Racheal Manhart</last_name>
      <phone>503-226-3376</phone>
    </contact>
    <investigator>
      <last_name>Pheobe Rich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Scott</last_name>
      <phone>979-774-5933</phone>
      <email>jscott@js-studies.com</email>
    </contact>
    <investigator>
      <last_name>Terry Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, P.A.,The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Herod</last_name>
      <phone>713-985-0210</phone>
      <email>aherod@sba-skincare.com</email>
    </contact>
    <investigator>
      <last_name>Suzanne Bruce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Rivera</last_name>
      <phone>757-625-0151</phone>
      <email>erivera@vcrinc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Pariser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
